Jun Ah Lee1, Dae-Geun Jeon2, Wan Hyeong Cho2, Won Seok Song2, Hoi Soo Yoon3, Hyeon Jin Park4, Byung Kiu Park4, Hyoung Soo Choi5, Hyo Seop Ahn5, Ji Won Lee6, Keon Hee Yoo6, Ki Woong Sung6, Hong Hoe Koo6, Hyoung Jin Kang7, Kyung Duk Park7, Hee Young Shin7, Kyung-Nam Koh8, Ho Joon Im8, Jong Jin Seo8, Yeon Jung Lim9, Hee Jo Baek10, Hoon Kook10. 1. Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Republic of Korea. 2. Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea. 3. Department of Pediatrics, Kyung Hee University School of Medicine, Seoul, Republic of Korea. 4. Center for Pediatric Oncology, National Cancer Center, Goyang, Seoul, Republic of Korea. 5. Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Seoul, Republic of Korea. 6. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 7. Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. 8. Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea. 9. Department of Pediatrics, Chungnam National University College of Medicine, Daejon, Republic of Korea. 10. Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea.
Abstract
BACKGROUND: Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated. METHODS: Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m(2) on days 1 and 8) and DOC (100 mg/m(2) on day 8), were retrospectively reviewed. RESULTS: GEM + DOC was administered as adjuvant (n = 25) or palliative chemotherapy (n = 28). Patients received a median 3 courses (range, 1-10 courses). Objective response rate (CR + PR, where CR is complete response and PR is partial response) and disease control rate (CR+ PR + SD, where SD is stable disease) were 14.3% and 28.6%, respectively. Disease control rate was higher in patients receiving 900 mg/m(2) GEM than in patients receiving 675 mg/m(2) (50.0% vs. 12.5%, P = 0.03). Higher GEM dose was associated with better survival, both in adjuvant (1-year overall survival, 90.9 ± 8.7% vs. 38.5 ± 13.5%, P = 0.002) and palliative settings (50.0 ± 14.4% vs. 31.3 ± 11.6%, P = 0.04). CONCLUSIONS: Further studies are necessary to investigate the efficacy of more aggressive and higher doses of GEM + DOC chemotherapy in osteosarcoma.
BACKGROUND: Efficacy of gemcitabine and docetaxel (GEM + DOC) chemotherapy in patients with recurrent or refractory osteosarcoma was evaluated. METHODS: Data of 53 patients from 9 institutions, who received GEM (675 or 900 mg/m(2) on days 1 and 8) and DOC (100 mg/m(2) on day 8), were retrospectively reviewed. RESULTS: GEM + DOC was administered as adjuvant (n = 25) or palliative chemotherapy (n = 28). Patients received a median 3 courses (range, 1-10 courses). Objective response rate (CR + PR, where CR is complete response and PR is partial response) and disease control rate (CR+ PR + SD, where SD is stable disease) were 14.3% and 28.6%, respectively. Disease control rate was higher in patients receiving 900 mg/m(2) GEM than in patients receiving 675 mg/m(2) (50.0% vs. 12.5%, P = 0.03). Higher GEM dose was associated with better survival, both in adjuvant (1-year overall survival, 90.9 ± 8.7% vs. 38.5 ± 13.5%, P = 0.002) and palliative settings (50.0 ± 14.4% vs. 31.3 ± 11.6%, P = 0.04). CONCLUSIONS: Further studies are necessary to investigate the efficacy of more aggressive and higher doses of GEM + DOC chemotherapy in osteosarcoma.
Authors: Ya Zhang; Jingqing Yang; Na Zhao; Cao Wang; Santosh Kamar; Yonghong Zhou; Zewei He; Jifei Yang; Bin Sun; Xiaoqian Shi; Lei Han; Zuozhang Yang Journal: Oncol Lett Date: 2018-09-12 Impact factor: 2.967
Authors: Valerae O Lewis; Eswaran Devarajan; Marina Cardó-Vila; Dafydd G Thomas; Eugenie S Kleinerman; Serena Marchiò; Richard L Sidman; Renata Pasqualini; Wadih Arap Journal: Proc Natl Acad Sci U S A Date: 2017-07-11 Impact factor: 11.205
Authors: Kelli L Goss; Stacia L Koppenhafer; Torin Waters; William W Terry; Kuo-Kuang Wen; Meng Wu; Jason Ostergaard; Peter M Gordon; David J Gordon Journal: Oncogene Date: 2020-11-15 Impact factor: 9.867